The efficacy of bimatoprost 0.03% monotherapy in patients previously using topical beta-blocker monotherapy for the treatment of glaucoma or ocular hypertension

Advances in Therapy

Volumn 21, Issue 6, 2004, Pages 370-379

  Quinones, Richard ^a   Earl, Melissa L ^b  

^a Arbor Center for Eye Care   (United States)

^b Innov Med/Epidemiologic Data S   (United States)

Author keywords

Bimatoprost; Ocular hypertension; Open angle glaucoma; Topical beta blockers

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIMATOPROST;

AGED; ARTICLE; CLINICAL TRIAL; CONJUNCTIVA DISEASE; CONJUNCTIVAL HYPEREMIA; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; EYE PAIN; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; VIRUS INFECTION;

EID: 14944347563     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02850101     Document Type: Article

References (21)

1. Jonsson B, Krieglstein G, Kobelt G, eds. Primary open-angle glaucoma: differences. In: International Treatment Patterns and Cost. London, England: Taylor & Francis, LTD; 1998.
2. Heijl A, Leske C, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression. Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-1279.
3. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713.
4. The AGIS Investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130: 429-440.
5. Brandt JD, VanDenburgh AM, Chen K, Whitcup SM, for the Bimatoprost Study Group I. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology. 2001;108:1023-1031; discussion 1032.
6. Higginbotham EJ, Schuman JS, Goldberg I, et al. One-year randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 2002;120:1286-1293.
7. Zimmerman T. Medicinal therapy for glaucoma. In: Eid TM, Spaeth GL, eds. The Glaucomas: Concepts and Fundamentals. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000:227-245.
8. McMahon CD, Shaffer RN, Hoskins HD Jr, Hetherington J Jr. Adverse effects experienced by patients taking timolol. Am J Ophthalmol. 1979;88:736-738.
9. Noecker RJ, Dirks MS, Choplin NT, et al. A six-month randomized clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135:55-63.
10. Netland PA, Landry T, Sullivan EK, et al, and the Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:472-484.
11. Singh K, Spaeth G, Zimmerman T, Minckler D. Target pressure- glaucomatologists' holey grail. Ophthalmology. 2000;107:629-630.
12. Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9:134-142.
13. Pillunat LE, Larsson LI; European and Canadian Latanoprost Study Group. Intraocular pressure after replacement of current dual therapy with latanoprost monotherapy in patients with open angle glaucoma. Br J Ophthalmol. 2003;87:1492-1496.
14. Dubiner HB, Sircy MD, Landry T, et al. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther. 2004;26:84-91.
15. Choplin N, Bernstein P, Batoosingh AL, Whitcup SM; Bimatoprost/ Latanoprost Study Group. A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure. Surv Ophthalmol. 2004;49(suppl 1):S19-S25.
16. Enright PL, McClelland RL, Newman AB, Gottlieb DJ, Lebowitz MD. Underdiagnosis and under-treatment of asthma in the elderly. Cardiovascular Health Study Research Group. Chest. 1999;116: 603-613.
17. Lama PJ. Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment. Am J Ophthalmol. 2002;134:749-760.
18. Valuck RJ, Perlman JI, Anderson C, Wortman GI. Co-prescribing of medications used to treat obstructive lung disease, congestive heart failure and depression among users of topical beta-blockers: estimates from three US Veterans Affairs Medical Centers. Pharmacoepidemiol Drug Saf. 2001;10:511-516.
19. Sherwood M, Brandt J, for the Bimatoprost Study Groups 1 and 2. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol. 2001;45 (suppl 4):S361-S368.
20. Schuman JS. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2. Ophthalmology. 2000;107:1171-1177.
21. Steinert RF, Thomas JV, Boger WP 3rd. Long-term drift and continued efficacy after multiyear timolol therapy. Arch Ophthalmol. 1981;99:100-103.